Jennison Associates’s Terns Pharmaceuticals TERN Stock Holding History

Jennison Associates’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-501,419	Closed	-$26.4M	–	624
2026 Q1	$26.4M	Buy	+501,419	New	+$20.6M	0.02%	295

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Jennison Associates's TERN Position: Q2 2026 in Review

Jennison Associates sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 501,419 shares — an estimated $26.4M sold.

Jennison Associates first reported a position in TERN in Q1 2026 and held it in 1 quarter. The position peaked at $26.4M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Jennison Associates reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Jennison Associates sold 501,419 Terns Pharmaceuticals shares in Q2 2026, an estimated $26.4M.
Jennison Associates first reported a position in Terns Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Jennison Associates's Terns Pharmaceuticals position peaked at $26.4M in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.